DUBLIN, May 22, 2020 –Nemysis Limited, the Dublin-based pharmaceutical and healthcare company, announced that it opened the Italian subsidiary Nemysis S.r.l.
Currently, Nemysis has three high-potential products in its development pipeline and, preparing to the market presence is the next crucial step in the expansion strategy of the company.
Danilo Casadei-Massari, Chairman and CEO of Nemsysis Ltd, believes that Italy can serve as a launchpad for future developments in Europe: “I am delighted that Nemysis has a continental Europe subsidiary now. Nemysis is looking forward to working in Italy as the well – established clinical expertise in the country adds important value to our R&D efforts and specifically our expeditious development of E40.”
Heading the Italian office will be Marco Cartolari – CEO of Nemysis S.r.l.- who, through his experience as CEO of Scharper Pharmaceuticals S.p.A., pioneered the nutraceutical market in Italy. Marco has deep expertise in bringing this class of products from the research stage into the market.
An integral part of Nemysis’ strategy is to cultivate and grow the company’s relationship with the Italian scientific community. According to Cartolari, “Italy represents one of the most developed food supplement markets, and the medical community is particularly open to the use of non-drug products to help patients, but only if backed by highly scientific validation. Our novel food products will fit this approach and establish new standards of quality in the nutraceutical market.”
Given the depth of experience in the Italian market by Nemysis’ management team, as well as the strong growth rates of the nutraceutical products market, Italy represents a unique opportunity for Nemysis’ commercial strategy.
Nemysis Ltd, a healthcare and pharmaceutical company, is focused on nutritional and pharmaceutical solutions which can protect against some of the negative consequences of nutrient deficiency, nutrient intolerances and sensitivities, paying particular attention to the need to safeguard the human microbiome.
- Nemysis’s novel nanoparticulate iron is the first natural ferritin mimic, which can correct human iron deficiency and anemia, without negatively impacting the gut microbiome. Safety and efficacy have been demonstrated in controlled-repeat-dose [clinical] trials.
- Nemysis’s novel E40 endopeptidase is gastric, trypsin and chymotrypsin resistant. It has been shown to destroy all the immuno-stimulatory epitopes of gluten, quenching the exacerbated inflammatory response of primed, gluten-sensitive and hyper-responsive human T cells. It is, therefore, suitable for the enzymatic management of gluten intolerance and sensitivity.
· Nemysis has three further products in its pipeline for use in Iron Deficiency/Anaemia, Gluten sensitivity and Celiac Disease
Find out more www.nemysisltd.com
Release date: May 22, 2020
Danilo Casadei -Massari
Chairman of the Board
7 D’Olier Street